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Preexposure Prophylaxis for the Prevention of HIV Infection
US Preventive Services Task Force
Recommendation Statement
US Preventive Services Task Force
T heUSPreventiveServicesTaskForce (USPSTF)makes rec-ommendations about theeffectivenessof specific preven-tivecare services forpatientswithoutobvious relatedsigns
or symptoms.
It bases its recommendations on the evidence of both the
benefits and harms of the service and an assessment of the bal-
ance. The USPSTF does not consider the costs of providing a ser-
vice in this assessment.
TheUSPSTFrecognizes that clinicaldecisions involvemorecon-
siderations than evidence alone. Clinicians should understand the
evidence but individualize decision making to the specific patient
or situation. Similarly, the USPSTF notes that policy and coverage
decisions involve considerations in addition to theevidenceof clini-
cal benefits and harms.
Summary of Recommendation and Evidence
TheUSPSTF recommends that cliniciansofferpreexposureprophy-
laxis (PrEP)witheffective antiretroviral therapy topersonswhoare
at high risk of HIV acquisition (A recommendation) (Figure 1).
See the Clinical Considerations section for information about
identification of persons at high risk and selection of effective
antiretroviral therapy.
IMPORTANCE An estimated 1.1 million individuals in the United States are currently living with
HIV, andmore than 700000 persons have died of AIDS since the first cases were reported in
1981. In 2017, there were 38 281 new diagnoses of HIV infection reported in the United States;
81% of these new diagnoses were amongmales and 19%were among females. Although
treatable, HIV infection has no cure and has significant health consequences.
OBJECTIVE To issue a new US Preventive Services Task Force (USPSTF) recommendation on
preexposure prophylaxis (PrEP) for the prevention of HIV infection.
EVIDENCE REVIEW The USPSTF reviewed the evidence on the benefits of PrEP for the
prevention of HIV infection with oral tenofovir disoproxil fumarate monotherapy or
combined tenofovir disoproxil fumarate and emtricitabine and whether the benefits vary by
risk group, population subgroup, or regimen or dosing strategy; the diagnostic accuracy of
risk assessment tools to identify persons at high risk of HIV acquisition; the rates of
adherence to PrEP in primary care settings; the association between adherence and
effectiveness of PrEP; and the harms of PrEP when used for HIV prevention.
FINDINGS The USPSTF found convincing evidence that PrEP is of substantial benefit
in decreasing the risk of HIV infection in persons at high risk of HIV acquisition.
The USPSTF also found convincing evidence that adherence to PrEP is highly associated with
its efficacy in preventing the acquisition of HIV infection; thus, adherence to PrEP is central
to realizing its benefit. The USPSTF found adequate evidence that PrEP is associated with
small harms, including kidney and gastrointestinal adverse effects. The USPSTF concludes
with high certainty that the magnitude of benefit of PrEP with oral tenofovir disoproxil
fumarate–based therapy to reduce the risk of acquisition of HIV infection in persons at high
risk is substantial.
CONCLUSIONS AND RECOMMENDATION The USPSTF recommends offering PrEPwith
effective antiretroviral therapy to persons at high risk of HIV acquisition.
(A recommendation)
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Rationale
Importance
An estimated 1.1 million individuals in the United States are cur-
rently living with HIV,1 andmore than 700000 persons have died
of AIDS since the first cases were reported in 1981.2 In 2017, there
were 38 281 newdiagnoses of HIV infection reported in theUnited
States;81%(30870)of thesenewdiagnoseswereamongmalesand
19% (7312) were among females.2 Although treatable, HIV infec-
tion has no cure and has significant health consequences.
Identification of Risk Status
AlthoughtheUSPSTFfound inadequateevidencethatspecific riskas-
sessment tools can accurately identify persons at high risk ofHIV ac-
quisition, it foundadequateepidemiologicdataonriskfactorsthatcan
be used to identify persons at high risk of acquiring HIV infection.
Benefits of PreventiveMedication
The USPSTF found convincing evidence that PrEP is of substantial
benefit fordecreasing the riskofHIV infection inpersonsathigh risk
ofHIV infection,eitherviasexualacquisitionorthrough injectiondrug
use. TheUSPSTFalso foundconvincingevidence that adherence to
Figure 1. USPSTF Grades and Levels of Evidence
What the USPSTF Grades Mean and Suggestions for Practice
Grade Definition
A The USPSTF recommends the service. There is high certainty that the net benefit is substantial. Offer or provide this service.
Suggestions for Practice
B The USPSTF recommends the service. There is high certainty that the net benefit is moderate, or
there is moderate certainty that the net benefit is moderate to substantial.
Offer or provide this service.
C
The USPSTF recommends selectively offering or providing this service to individual patients
based on professional judgment and patient preferences. There is at least moderate certainty
that the net benefit is small.
Offer or provide this service for selected
patients depending on individual
circumstances.
D The USPSTF recommends against the service. There is moderate or high certainty that the service
has no net benefit or that the harms outweigh the benefits.
Discourage the use of this service.
I statement
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits
and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of
benefits and harms cannot be determined.
Read the Clinical Considerations section
of the USPSTF Recommendation
Statement. If the service is offered,
patients should understand the
uncertainty about the balance of benefits
and harms.
USPSTF Levels of Certainty Regarding Net Benefit
Level of Certainty Description
High
The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care
populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be
strongly affected by the results of future studies.
Moderate
The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate
is constrained by such factors as 
the number, size, or quality of individual studies.
inconsistency of findings across individual studies.
limited generalizability of findings to routine primary care practice.
lack of coherence in the chain of evidence.
As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large
enough to alter the conclusion.
The USPSTF defines certainty as “likelihood that the USPSTF assessment of the net benefit of a preventive service is correct.” The net benefit is defined as
benefit minus harm of the preventive service as implemented in a general, primary care population. The USPSTF assigns a certainty level based on the nature
of the overall evidence available to assess the net benefit of a preventive service.
Low
The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of
the limited number or size of studies.
important flaws in study design or methods.
inconsistency of findings across individual studies.
gaps in the chain of evidence.
findings not generalizable to routine primary care practice.
lack of information on important health outcomes.
More information may allow estimation of effects on health outcomes.
USPSTF indicates US Preventive Services Task Force.
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PrEP is highly correlatedwith its efficacy in preventing the acquisi-
tion of HIV infection.
Harms of PreventiveMedication
TheUSPSTF found adequate evidence that PrEP is associatedwith
small harms, including kidney and gastrointestinal adverse effects.
USPSTF Assessment
The USPSTF concludes with high certainty that the net benefit of
the use of PrEP to reduce the risk of acquisition of HIV infection in
persons at high risk of HIV infection is substantial.
Clinical Considerations
Patient Population Under Consideration
This recommendation applies topersonswhoarenot infectedwith
HIV and are at high risk of HIV infection (Figure 2).
Assessment of Risk
Although the USPSTF found no well-validated, accurate tools to
assess risk of HIV acquisition, epidemiologic data, Centers for Dis-
ease Control and Prevention (CDC) guidelines,3 and enrollment
criteria for clinical trials provide guidance on detecting persons
who may be at high risk. Persons at risk of HIV infection include
men who have sex with men, persons at risk via heterosexual
contact, and persons who inject drugs. Within these groups, cer-
tain risk factors or behaviors (outlined below) can place persons
at high risk of HIV infection.
It is important to note that men who have sex with men and
heterosexually active persons are not considered to be at high
risk if they are in a mutually monogamous relationship with a
partner who has recently tested negative for HIV. In addition, all
persons being considered for PrEP must have a recently docu-
mented negative HIV test result.
The USPSTF recommends that the following persons be con-
sidered for PrEP:
Figure 2. Clinical Summary: Preexposure Prophylaxis for the Prevention of HIV Infection
Population
Recommendation 
Persons at high risk of HIV acquisition
Offer preexposure prophylaxis (PrEP).
Grade: A
Risk Assessment
Relevant USPSTF
Recommendations
Preventive
Medication
For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please
go to https://www.uspreventiveservicestaskforce.org.   
Persons at risk of HIV infection include men who have sex with men, persons at risk via heterosexual contact, and persons who
inject drugs. Within these groups, certain risk factors or behaviors (outlined below) can place persons at high risk of HIV infection.
Men who have sex with men, are sexually active, and have 1 of the following characteristics: 
• A serodiscordant sex partner (ie, in a sexual relationship with a partner living with HIV)
• Inconsistent use of condoms during receptive or insertive anal sex
• An STI with syphilis, gonorrhea, or chlamydia within the past 6 months
Heterosexually active women and men who have 1 of the following characteristics: 
• A serodiscordant sex partner (ie, in a sexual relationship with a partner living with HIV) 
• Inconsistent use of condoms during sex with a partner whose HIV status is unknown and who is at high risk (eg, a person who
injects drugs or a man who has sex with men and women)
• An STI with syphilis or gonorrhea within the past 6 months 
Persons who inject drugs and have 1 of the following characteristics: 
• Shared use of drug injection equipment 
• Risk of sexual acquisition of HIV (see above)
Persons who engage in transactional sex, persons who are trafficked for sex work, men who have sex with men and women, 
and transgender women and men who are sexually active can be at high risk of HIV infection and should be considered for PrEP
based on the criteria outlined above. 
The USPSTF has issued recommendations on behavioral counseling to reduce risk of STIs and on screening for HIV infection.
Once-daily oral treatment with combined tenofovir disoproxil fumarate and emtricitabine is the only formulation of PrEP
currently approved by the US Food and Drug Administration for use in the United States in persons at risk of sexual acquisition
of HIV infection.
STI indicates sexually transmitted infection; USPSTF, US Preventive Services Task Force.
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1. Men who have sex with men, are sexually active, and have
1 of the following characteristics:
• A serodiscordant sex partner (ie, in a sexual relationship with
a partner living with HIV)
• Inconsistent use of condoms during receptive or insertive
anal sex
• A sexually transmitted infection (STI)with syphilis, gonorrhea,
or chlamydia within the past 6months
2. Heterosexually activewomenandmenwhohave 1of the follow-
ing characteristics:
• A serodiscordant sex partner (ie, in a sexual relationship with
a partner living with HIV)
• Inconsistent use of condoms during sex with a partner whose
HIV status is unknownandwho is at high risk (eg, apersonwho
injects drugs or a man who has sex with men and women)
• An STI with syphilis or gonorrhea within the past 6months
3. Persons who inject drugs and have 1 of the following charac-
teristics:
• Shared use of drug injection equipment
• Risk of sexual acquisition of HIV (see above)
Personswhoengage in transactional sex, suchas sex formoney,
drugs,orhousing, includingcommercial sexworkersorpersons traf-
ficked for sexwork, constitute another group at high risk of HIV ac-
quisitionandshouldbeconsideredforPrEPbasedonthecriteriaout-
lined above. Menwho have sex withmen andwomen are at risk of
HIV acquisition and should be evaluated for PrEP according to the
criteria outlined above formenwhohave sexwithmenandhetero-
sexually active men.
Transgender women and men who are sexually active may be
at increasedriskofHIVacquisitionandshouldbeconsideredforPrEP
basedon the criteria outlinedabove. Transgenderwomenare at es-
peciallyhigh riskofHIVacquisition.TheCDCestimates that approxi-
mately one-fourth of transgender women are living with HIV, and
more thanhalf (anestimated56%)ofblack/AfricanAmerican trans-
gender women are living with HIV.4 Although trials of PrEP en-
rolled few transgender women and no trials have been conducted
among transgender men, PrEP has been shown to reduce the risk
ofHIVacquisitionduring receptiveand insertiveanalandvaginal sex.
Therefore, its use may be considered in all persons (cisgender and
transgender) at high risk of sexual acquisition of HIV.
Consistent useof condomsdecreases riskofHIVacquisitionby
approximately80%5andalsodecreases the riskofotherSTIs.How-
ever, sexually activeadultsoftenusecondoms inconsistently.6PrEP
should be considered as an option to reduce the risk of HIV acqui-
sition in persons who use condoms inconsistently, while continu-
ing to encourage and support consistent condom use.
Todate, in3 studies, transmissionofHIV toa seronegativepart-
ner from a partner livingwithHIV has not been observedwhen the
seropositive partner was being treated with antiretroviral therapy
andhada suppressedviral load.7-9 It is not knownwhetherPrEPuse
further decreases the risk of HIV transmission when a seropositive
partner has a documented undetectable viral load.
The risk of acquisition of HIV infection is on a continuum. This
riskdependson the likelihood thata specific actor activitywill trans-
mit HIV and the likelihood that a sex partner or drug injection part-
ner is living with HIV. The likelihood of HIV transmission is highest
with needle-sharing injection drug use and condomless receptive
anal intercourse, whereas condomless insertive anal sex and con-
domless receptive and insertive penile-vaginal sex have a risk of
transmission that is approximately 10- to 15-fold lower than recep-
tive anal intercourse.5 One recent study estimated the prevalence
of HIV (ie, the likelihood that a partner whose HIV status is un-
known is living with HIV) as 12.4% among men who have sex with
men and 1.9%among personswho inject drugs,10 although an ear-
lier systematic review estimated the prevalence of HIV among per-
sonswho inject drugs tobemuchhigher (16%).11 Theprevalenceof
HIV among men who have sex with men and women is estimated
tobe intermediatebetweenthatofmenwhohavesexwithmenand
heterosexually active men.12 Thus, persons at high risk of HIV ac-
quisition via penile-vaginal intercourse, including those with a re-
cent bacterial STI acquired via penile-vaginal intercourse, will gen-
erallybeat lowerabsolute risk thanpersonsathigh riskvia receptive
anal intercourse or injection drug use. These are factors that clini-
cians and patients can consider as they discuss the use of PrEP for
HIV prevention.
In addition, risk behaviors should be interpreted in the context
of the HIV prevalence in a community or network; that is, risk be-
haviors in a high-prevalence setting carry a higher risk of acquiring
HIV infection than the same behaviors in a low-prevalence setting.
The threshold of HIV prevalence below which PrEP has insignifi-
cant net benefit is not known.
PreventiveMedication
Once-daily oral treatment with combined tenofovir disoproxil
fumarate and emtricitabine is the only formulation of PrEP
approved by the US Food and Drug Administration (FDA) for use in
the United States in persons at risk of sexual acquisition of HIV
infection. However, several studies reviewed by the USPSTF found
that tenofovir disoproxil fumarate alone was also effective as PrEP,
and CDC guidelines note that, given these trial data, tenofovir diso-
proxil fumarate alone can be considered as an alternative regimen
for high-risk heterosexually active men and women and persons
who inject drugs.3
According to its product label, tenofovir disoproxil fumarate/
emtricitabinemaybeconsidered foruseasPrEPduringpregnancy.13
No trials of oral PrEP included pregnant women; however, preg-
nancy is associatedwith an increased risk of HIV acquisition.14 CDC
guidelines recommendshareddecisionmaking forpregnantwomen
who are considering starting or continuing PrEP during pregnancy.
Adolescents at high risk of HIV acquisition could benefit from
PrEP, and tenofovir disoproxil fumarate/emtricitabine is approved
by theFDAforuseasPrEP inadolescentswhoweighat least 35kg.13
In addition, young men who have sex with men are at particularly
high riskofHIVacquisition.15However, no randomizedclinical trials
(RCTs)ofPrEPenrolledadolescents. Limiteddata suggest thatPrEP
use is not associatedwith significant adverse events in adolescents
but may be associated with slightly less bone mineral accrual than
wouldbeexpected.16 TheUSPSTF suggests that cliniciansweighall
these factorswhen consideringPrEPuse in adolescents at high risk
ofHIVacquisition. In addition, cliniciansneed tobeawareof any lo-
cal laws and regulations thatmay apply when providing PrEP to an
adolescent minor.
Additional Approaches to Prevention
Several additional approaches for decreasing risk of HIV acquisi-
tion are also available. Consistent use of condomsdecreases risk of
Clinical Review& Education US Preventive Services Task Force USPSTF Recommendation: Preexposure Prophylaxis for the Prevention of HIV Infection
2206 JAMA June 11, 2019 Volume 321, Number 22 (Reprinted) jama.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 07/30/2019
HIVacquisitionbyapproximately80%5andreduces theriskofother
STIs. The USPSTF recommends intensive behavioral counseling to
reduce behaviors associatedwith increased risk of STIs andHIV ac-
quisitionand to increasecondomuseamongadolescentsandadults
at increased risk of STIs.17 TheCDChasmade several recommenda-
tions, including abstinence, reducingone’s numberof sexpartners,
andconsistent condomuse, todecrease riskofSTIs, includingHIV.18
TheCDCalso recommends syringe service programs (ie, needle ex-
change programs) to reduce the risk of HIV acquisition and trans-
mission among persons who inject drugs.19 The Community Pre-
ventiveServicesTaskForcehasalso issuedseveral recommendations
on the prevention of HIV and other STIs.20 Postexposure prophy-
laxis, startedas soonaspossibleafter apossibleexposureevent, can
also decrease the risk of HIV infection.
Screening forHIV infection todetectundiagnosedcasesandan-
tiretroviral treatment inpersons livingwithHIVtosuppressviral load
are both important approaches to decreasing the risk of HIV trans-
mission at the population level, while also benefiting the individual
living with HIV. The USPSTF recommends screening for HIV infec-
tion in adolescents and adults aged 15 to 65 years, younger adoles-
cents and older adults at increased risk, and all pregnant persons.21
Useful Resources
The CDC guidelines on PrEP for the prevention of HIV infection are
available at https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-
prep-guidelines-2017.pdf3 and https://www.cdc.gov/hiv/pdf/risk/
prep/cdc-hiv-prep-provider-supplement-2017.pdf.22AdditionalCDC
resources on PrEP for both clinicians and consumers are available
at https://www.cdc.gov/hiv/risk/prep/index.html.23 Community-
level HIV prevalence data for the United States are available at
https://www.cdc.gov/nchhstp/atlas.24 The USPSTF has issued rec-
ommendationsonbehavioral counseling to reduce riskofSTIs17 and
on screening for HIV infection.21
Other Considerations
Implementation
The first step in implementingPrEP is identifyingpersonsathigh risk
of HIV acquisition who may benefit from PrEP. However, identify-
ing persons at risk of HIV can be challenging because of stigma and
discriminationagainstgay,bisexual, transgender, andnonbinaryper-
sons, or the lack of a trusting relationship between the patient and
clinician. It is important that clinicians routinely takea sexual and in-
jection drug use history for all their patients in an open and non-
judgmental manner. If a person is identified as potentially belong-
ingtoahigh-riskgroup, thenfurtherdiscussioncan identifybehaviors
that maymake that person an appropriate candidate for PrEP.
TheCDCprovidesacompletediscussionof implementationcon-
siderations for PrEP, including baseline and follow-up testing and
monitoring, time to achieving protection, and discontinuing PrEP.3
A fewparticularly important points regarding the provision of PrEP
are outlined below.
Before prescribing PrEP, clinicians should exclude persons
with acute or chronic HIV infection through taking a medical his-
tory and HIV testing. The 2-drug antiretroviral regimen used in
PrEP, when used alone, is not an effective treatment for HIV
infection, and its use in persons living with HIV can lead to the
emergence of, or selection for, drug-resistant HIV infection. It is
also generally recommended that kidney function testing, sero-
logic testing for hepatitis B and C virus, testing for other STIs, and
pregnancy testing (when appropriate) be conducted at the time
of or just before initiating PrEP. Ongoing follow-up and monitor-
ing, including HIV testing every 3 months, is also suggested.
The time from initiation of PrEP to achieving protection against
HIV infection is unknown. Pharmacokinetic data suggest that
maximum levels of tenofovir diphosphate (the active form of
tenofovir) is reached in 7 days in rectal tissue and in 20 days in
blood (peripheral blood mononuclear cells) and vaginal tissue.3
Patients can continue PrEP as long as high risk of HIV acquisition
continues. Patients may discontinue PrEP for several reasons,
including personal preference, decreased risk of HIV acquisition,
or adverse medication effects.
PrEP does not reduce the risk of other STIs. Consistent use of
condomsdecreases risk ofHIV acquisition by approximately 80%5
andreduces the riskofotherSTIs.Promotingconsistentcondomuse
is an important component of a successful PrEP program. The CDC
also recommends regular screening for STIs in men who have sex
withmenwhoareathighriskofSTIs, andtesting inanyonewithsigns
or symptoms.3
Clinical trials demonstrate a strong connection between adher-
ence to PrEP and its effectiveness in preventing HIV acquisition.
Reduced adherence is associatedwithmarked declines in effective-
ness. Therefore, adherence support is a key component of provid-
ing PrEP. Components of adherence support include establishing
trust and open communication with patients, patient education,
reminder systems for taking medication, and attention to medica-
tion adverse effects and having a plan to address them. Additional
information on adherence support is available from the CDC
guidelines.3,22 Adherence support is especially important in popu-
lations shown to have lower adherence to PrEP, such as young per-
sons and racial/ethnic minorities.25-27
It is important for clinicians to recognize that barriers to the
implementation and uptake of PrEP exist. These barriers can
include structural barriers, such as lack of health insurance, and
other factors, such as an individual’s willingness to believe that he
or she is an appropriate candidate for PrEP or to take PrEP. There
are also racial/ethnic disparities in the use of PrEP. One study
reported that although black/African American persons account for
an estimated 44% of all new HIV infections in the United States,
only 10.1% of those who initiated PrEP from 2012 to 2015 were
black/African American. Similarly, black women, who are also dis-
proportionately affected by HIV, were more than 4 times less likely
to have initiated PrEP than white women.28 These barriers and dis-
parities need to be addressed to achieve the full benefit of PrEP.
Research Needs and Gaps
Research is needed to develop and validate tools that are highly
accurate for identifying persons at high risk of HIV acquisition who
would benefit from PrEP. When developed and validated, risk
assessment instruments should include those populations most at
risk of HIV infection, particularly racial/ethnic minorities such as
black/African American and Hispanic/Latino populations.
Research isneededondifferentdrug regimensanddosingstrat-
egies forPrEP.Several trials investigatingdifferentantiretroviraldrugs
or drug regimens for use as PrEP are ongoing.
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Research isneededonfactorsassociatedwithadherencetoPrEP
andmethods to increaseuptakeandadherence, especially inpopu-
lations with lower use of and adherence to PrEP, such as younger
persons and racial/ethnic minorities.
TrialsordemonstrationprojectsofPrEP inUSpopulationsofhet-
erosexual persons, persons who inject drugs, and transgender
womenandmenareneededtobetterquantifyeffectiveness in those
populations. Research is neededon the safety and effectiveness of
PrEP during pregnancy and breastfeeding. Additional research is
needed todeterminewhether theuseof PrEP is associatedwith an
increased risk of other STIs. Research is also needed on the long-
term safety and effectiveness of PrEP.
Discussion
Burden of Disease
Since the first cases of AIDS were reported in 1981, more than
700000persons in theUnited States have died of AIDS.2 The CDC
estimates that 1.1 million individuals in the United States are cur-
rently livingwithHIV infection,1 includinganestimated 15%whoare
unaware of their infection.10 The annual number of new HIV infec-
tions intheUnitedStateshasdecreasedfromabout41 200newcases
in2012to38300in2017.2OfthesenewcasesofHIVinfection in2017,
81%wereamongmales and 19%wereamong females.2Groupsdis-
proportionately affected by HIV infection in the United States in-
cludemenwhohave sexwithmen, black/AfricanAmerican popula-
tions, and Hispanic/Latino populations. From 2012 to 2017, HIV
incidence rates increased among persons aged 25 to 29 years and
among American Indian/Alaska Native and Asian populations.2
PrEP is currently not used in many persons at high risk of HIV
infection. The CDC estimates that approximately 1.2 million per-
sonswereeligible forPrEP in2015 (492000menwhohavesexwith
men, 115 000personswho inject drugs, and624000heterosexu-
ally active adults),29 anda recent studyestimates that 100 282per-
sons were using PrEP in 2017.30
Scope of Review
For this recommendation, theUSPSTF commissioned a systematic
review31,32 of the evidence on the benefits of PrEP for the preven-
tion of HIV infectionwith oral tenofovir disoproxil fumaratemono-
therapyor tenofovir disoproxil fumarate/emtricitabine (referred to
simply as “PrEP” hereafter) and whether the benefits vary by risk
group, population subgroup, or regimen or dosing strategy; the di-
agnosticaccuracyof riskassessment tools to identifypersonsathigh
riskofHIVacquisition; the ratesofadherence toPrEP inprimarycare
settings; the association between adherence and effectiveness of
PrEP; and the harms of PrEP when used for HIV prevention.
Effectiveness of Risk Assessment
The USPSTF found 7 studies that evaluated risk assessment tools
developed in US cohorts for predicting incident HIV infection—6
studies in men who have sex with men33-38 and 1 study in persons
who inject drugs.39 The USPSTF found no studies in US cohorts
evaluating tools for predicting risk of HIV infection in men and
women at increased risk of HIV infection via heterosexual con-
tact. In those studies that reported it, discrimination of the risk
prediction instrument was moderate, with an area under the
receiver operating characteristic curve of 0.66 to 0.72. However,
each study evaluated a different risk prediction tool. Some instru-
ments were not validated in independent cohorts, and several
instruments were developed and validated using older (ie, before
2000) cohorts. Most of the studies of risk prediction tools in
men who have sex with men were developed in predominantly
white populations, and 2 studies found that several of the instru-
ments performed more poorly in black men who have sex with
men (area under the receiver operating characteristic curve,
0.49-0.63).37,38 All tools are predicated on knowing that a person
belongs to an HIV risk group; no tool has been designed to predict
incident HIV infection in persons not already identified as belong-
ing to an HIV risk group.31
The USPSTF considered several factors in its assessment of risk
of HIV acquisition, including the prevalence of HIV infection within
a group and the risk that a specific behavior or action will lead to
acquisition of HIV infection. As discussed in the Assessment of Risk
section, 1 study estimated the prevalence of HIV infection among
men who have sex with men to be 12.4%; persons who inject
drugs, 1.9%; and the overall population 13 years and older, 0.4%,10
although another study estimated a significantly higher prevalence
(16%) among persons who inject drugs.11 In terms of risk of HIV
acquisition from specific behaviors, receptive anal intercourse
without a condom and needle-sharing injection drug use carry the
highest risk, whereas insertive anal intercourse, receptive penile-
vaginal intercourse, and insertive penile-vaginal intercourse carry
lower but not negligible risks of acquiring HIV from a partner or
source who is seropositive for HIV.5
Effectiveness of PreventiveMedication
The USPSTF found 12 RCTs that evaluated the effect of PrEP
vs placebo25,40-49 or no PrEP50 on the risk of HIV acquisition.
One trial was of fair quality because of an open-label design;
all other trials were of good quality. Duration of follow-up ranged
from 4 months to 4 years. Six trials42-44,47-49 enrolled men and
women at increased risk of HIV infection via heterosexual contact,
4 trials25,40,46,50 enrolledmenwho have sex with men or transgen-
der women, 1 trial41 enrolled high-risk women and men who have
sex with men, and 1 trial45 enrolled persons who inject drugs.
No trial enrolled pregnant women or persons younger than 18
years. Three trials25,45,47 evaluated tenofovir disoproxil fumarate
(300 mg), 7 trials40-42,46,48,49 evaluated tenofovir disoproxil
fumarate (300 mg)/emtricitabine (200 mg), 1 trial50 evaluated
tenofovir disoproxil fumarate (245 mg)/emtricitabine (200 mg),
and 2 trials43,44 included study groups for both tenofovir disoproxil
fumarate (300 mg) alone and tenofovir disoproxil fumarate
(300 mg)/emtricitabine (200 mg). PrEP was prescribed daily in 11
trials,25,41-50 and dosing was intermittent or event-driven in 3 trials
(including 2 trials that also included daily dosing groups).40-42
Seven trials were conducted in Africa,41-44,47-49 1 in Thailand,45 2 in
Europe or Canada,40,50 and 1 in the United States25; 1 trial was
multinational.46 All trials of persons at high risk of HIV infection via
heterosexual contact were conducted in Africa, and the only trial of
persons who inject drugs was conducted in Thailand.45 All trials of
PrEP also included behavioral and adherence counseling, and most
specified providing condoms to all trial participants.
Onesmall trial reportednocasesofHIV infection.42 In theother
11 trials, the rate of HIV infection ranged from 1.4% to 7.0% over 4
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months to 4 years in participants randomly assigned to placebo or
no PrEP and from0% to 5.6% in those randomly assigned to PrEP.
In a meta-analysis of these trials, PrEP was associated with re-
duced risk of HIV infection compared with placebo or no PrEP
(relative risk [RR], 0.46 [95% CI, 0.33-0.66]; absolute risk reduc-
tion,−2.0%[95%CI,−2.8%to−1.2%])after4months to4years.31,32
PrEP was effective across population subgroups defined by
HIV risk category. There were no statistically significant differences
in estimates of effectiveness for PrEP vs placebo or no PrEP in risk
of HIV acquisition when trials were stratified according to whether
they enrolled men who have sex with men or transgender women
(although the number of transgender persons in trials was small) (4
trials; RR, 0.23 [95% CI, 0.08-0.62]), men andwomen at increased
risk of HIV infection via heterosexual contact (5 trials; RR, 0.54
[95% CI, 0.31-0.97]), or persons who inject drugs (1 trial; RR, 0.52
[95% CI, 0.29-0.92]; P = .43 for interaction).31,32
In a meta-analysis of the trials reviewed by the USPSTF, both
tenofovir disoproxil fumarate/emtricitabine and tenofovir diso-
proxil fumarate alone appeared equally effective in decreasing the
risk of HIV acquisition (8 trials; RR, 0.44 [95% CI, 0.27-0.72] and 5
trials; RR, 0.49 [95% CI, 0.28-0.84], respectively; P = .79 for
interaction).31,32
Three included trials investigated alternative dosing strategies
(using PrEP less frequently than daily [intermittent dosing] or be-
foreandafterHIVexposureevents [event-drivendosing]).40-42One
trial42 reported no HIV events, and a second41 did not report re-
sults for intermittentanddailydosingofPrEPgroupsseparately.The
third trial (InterventionPréventivede l’Exposition auxRisques avec
et pour les Gays) found that event-driven PrEP dosing was associ-
atedwitha lower riskofHIV infectioncomparedwithplacebo inmen
whohavesexwithmen(RR,0.14[95%CI,0.03-0.63]).40 In that trial,
men randomly assigned to PrEP took an average of about 4 doses
of PrEP per week (15 doses per month), so it is uncertain whether
this finding would apply to less frequent use of event-driven dos-
ing. Inaddition, tenofovirdisoproxil fumarateaccumulatesmorerap-
idly in anal tissue thanvaginal tissue,51 so this studymaynotbegen-
eralizable to other risk groups.
TheUSPSTFalsoevaluated theevidenceon the relationshipbe-
tween adherence to PrEP and its effectiveness in decreasing risk of
HIV infection.Methods for evaluating adherencedifferedbetween
studies and included patient diaries and self-report, pill counts, ad-
herencemonitoring devices, drug levels (eg, plasma or dried blood
spots), and prescription fill data.
In the trials ofPrEP reviewedby theUSPSTF, adherence toPrEP
ranged from 30% to 100%, and the RR of HIV infection in partici-
pants randomlyassignedtoPrEP,comparedwithplaceboornoPrEP,
ranged from0.95 to 0.07.31,32 In a stratified analysis of these stud-
ies, a strong interaction (P < .00001) between level of adherence
and effectiveness of PrEP was found, with higher levels of adher-
ence associated with greater reduction in risk of HIV acquisition
(adherence70%: 6 trials; RR, 0.27 [95% CI, 0.19-0.39]; adher-
ence >40%to<70%:3 trials; RR,0.51 [95%CI,0.38-0.70]; and ad-
herence40%: 2 trials; RR, 0.93 [95% CI, 0.72-1.20]).31,32 There
was also a strong association (P < .0005) between adherence and
effectiveness when adherence was analyzed as a continuous vari-
able in a meta-regression.31,32
Since the effectiveness of PrEP is closely tied to adherence,
the USPSTF reviewed the evidence on levels of adherence to PrEP
in US-relevant settings. Three observational studies of US men
who have sex with men found adherence to PrEP (based on teno-
fovir diphosphate levels in dried blood spot sampling consistent
with 4 doses/wk) of 66% to 90% over 4 to 48 weeks.27,52,53
Two observational studies of younger men who have sex with
men (mean ages, 20 and 16 years) reported lower rates of adher-
ence to PrEP (based on blood spot sampling) of approximately
50% at 12 weeks, decreasing to 34% and 22% at 48 weeks.16,54
Two studies in US men who have sex with men found that self-
reported adherence correlated highly with adherence based on
dried blood spot sampling.25,26
Multivariate analysis of the largest US PrEP implementation
study todate53 found that black racewas associatedwith lower ad-
herence than white race (adjusted odds ratio, 0.28 [95% CI, 0.12-
0.64]). Having stable housing or having receptive anal sexwithout
a condom with 2 or more partners was associated with increased
adherence (adjusted odds ratio, 2.02 [95% CI, 1.14-3.55] and 1.82
[95% CI, 1.14-2.89], respectively). There was no association be-
tween age, educational attainment, income level, health insurance
status, and alcohol or druguse andadherence.Only 1.4%ofpartici-
pantsenrolledwere transgenderwomen, so it isnotpossible todraw
conclusionsaboutadherencetoPrEP in thispopulation.TheUSPSTF
found no US studies on factors associated with adherence to PrEP
in persons who inject drugs or persons at high risk of HIV infection
via heterosexual contact.31
Potential Harms of Risk Assessment
and PreventiveMedication
The RCTs that investigated the effectiveness of PrEP had 4months
to 4 years of follow-up and also reported on the harms of
PrEP.25,40-50,55-62 In a pooled analysis of these studies, PrEP was
associated with increased risk of renal adverse events (primarily
grade 1 or greater serum creatinine elevation) vs placebo (12 trials;
absolute risk difference, 0.56% [95% CI, 0.09%-1.04%]). There
was no clear difference in risk of kidney adverse events when trials
were stratified according to use of tenofovir disoproxil fumarate
monotherapy or tenofovir disoproxil fumarate/emtricitabine. Seri-
ous renal events were rare, and no trial reported a difference
between PrEP and placebo in risk of serious renal events or with-
drawals due to renal events.31,32 Six trials41,42,55-58 evaluated
whether renal adverse events while using PrEP were persistent.
Three studies55,57,58 reported a return to normal serum creatinine
levels after cessation of PrEP, and 2 others41,42 reported normaliza-
tion of creatinine level without PrEP cessation. In 1 trial, the Bang-
kok Tenofovir Study of persons who inject drugs, there were 7
cases of grade 2 or greater creatinine level elevation, and all but 1
case resolved after PrEP cessation.56
PrEPwas associatedwith increased risk of gastrointestinal ad-
verse events (primarily nausea) vs placebo (12 trials; absolute risk
difference, 1.95%[95%CI,0.48%-3.43%]). The risk of gastrointes-
tinal adverseevents increasedwithboth tenofovir disoproxil fuma-
ratemonotherapyandtenofovirdisoproxil fumarate/emtricitabine,31
with risk diminishing over time in 3 trials.45,46,48 Serious gastroin-
testinal eventswere rare in trials reporting thisoutcome,withnodif-
ferences between PrEP and placebo.44,46-50
Tenofovir disoproxil fumarateexposure is associatedwithbone
loss,48,59-61 which could result in increased fracture risk. A meta-
analysisof7studies that reportedonfractures,usingbothstudydata
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and updated fracture data reported to the FDA, found a statisti-
cally nonsignificant increased risk of fracture in persons randomly
assigned to PrEP vs placebo. This result was also heavily weighted
by the 1 study of PrEP in persons who inject drugs, which reported
a relatively high fracture rate.31,32
One concern about PrEP is that its use may lead to persons at
risk of HIV acquisition not using condoms or engaging in other be-
haviors that could increase their riskof STIs (ie, behavioral risk com-
pensation). In meta-analyses of the studies reviewed by the
USPSTF, therewerenodifferencesbetweenPrEPandplaceboorno
PrEP in risk of syphilis (4 trials; RR, 1.08 [95% CI, 0.98-1.18]), gon-
orrhea (5 trials;RR, 1.07 [95%CI,0.82-1.39]), chlamydia (5 trials;RR,
0.97 [95% CI, 0.80-1.18]), or combined bacterial STIs (2 trials; RR,
1.14 [95%CI,0.97-1.34]).31,32Allof thetrialsexcept for 1wereblinded,
whichcouldaffect riskofSTIs if participantswhodonotknow if they
are takingPrEPorplacebobehavedifferently than thosewhoknow
they are taking PrEP. In the 1 open-label trial, therewas also no sta-
tistically significant associationbetweenPrEPand the riskof STIs.50
An additional concern is the possibility that the use of antiret-
roviral drugs as PrEP could lead to the development or acquisition
of drug-resistant HIV infection. In 8 trials of PrEP using tenofovir
disoproxil fumarate monotherapy or tenofovir disoproxil
fumarate/emtricitabine, 3 of 282 patients (1.1%) newly diagnosed
with HIV infection while taking PrEP had tenofovir resistance
mutations.40,43-47,49,50 In 6 trials of PrEP with tenofovir disoproxil
fumarate/emtricitabine, 14 of 174 patients (8.0%) newly diag-
nosed with HIV infection while taking PrEP had emtricitabine
resistance mutations.40,43,44,46,48-50 There was 1 case of multiple
resistance mutations, which is included in the total number of
both tenofovir and emtricitabine resistance mutations. Most
resistance mutations (1/2 tenofovir resistance mutations, 8/13
emtricitabine resistance mutations, and 1 case of multiple resis-
tance mutations, or 63% of total cases) occurred in persons who
were already infected with HIV on trial enrollment but were not
recognized as such. This highlights the importance of testing for
HIV and excluding persons with acute or chronic HIV infection
before initiating PrEP. The USPSTF found no data on the effect of
resistance mutations on clinical outcomes.
No trial of oral PrEP enrolled pregnant women, and women
who became pregnant during the course of the trials were with-
drawn from participation. Three trials reported on pregnancy
outcomes in women who were withdrawn from PrEP because of
pregnancy.41,48,62Amongwomenwhobecamepregnant in thetrials,
PrEP was not associated with increased risk of spontaneous abor-
tion. One trial, the Partners PrEP trial, also found no differences be-
tween PrEP and placebo in pregnancy rate, risk of preterm birth,
birth anomalies, or postpartum infantmortality.62
Estimate ofMagnitude of Net Benefit
The USPSTF found convincing evidence that PrEP is of substantial
benefit in decreasing the risk ofHIV infection in persons at high risk
ofHIVacquisition. TheUSPSTFalso foundconvincingevidence that
adherence to PrEP is highly correlated with its efficacy in prevent-
ing the acquisition of HIV infection; thus, adherence to PrEP is cen-
tral to realizing its benefit. The USPSTF found adequate evidence
that PrEP is associated with small harms, including renal and gas-
trointestinal adverse effects. TheUSPSTF concludeswith high cer-
tainty that themagnitudeofbenefit ofPrEPwithoral tenofovirdiso-
proxil fumarate–based therapy to reduce the risk of acquisition of
HIV infection in persons at high risk is substantial.
HowDoes Evidence FitWith Biological Understanding?
HIV isanRNAretrovirus that infects immunecells, inparticularCD4+
T cells. Antiretroviral agents interferewith 1 of several steps in viral
infection and replication, such asHIV entry intoCD4+ cells, reverse
transcriptionof viral RNA intoDNA, integrationof the viral genome
into the host genome, and assembly of HIV proteins and RNA into
newvirus.63Tenofovirdisoproxil fumarateandemtricitabineareboth
reverse transcriptase inhibitors and have favorable safety profiles.
Tenofovir disoproxil fumarate achievesparticularly high concentra-
tions in rectal tissue, and emtricitabine achieves high concentra-
tions in the female genital tract.64 The possibility of using PrEP to
prevent HIV transmissionwas suggested by the success of antiret-
roviral agents inpreventingmother-to child transmissionofHIVand
their use as postexposure prophylaxis65-67 and was demonstrated
in several animal models, including 1model showing that tenofovir
disoproxil fumarate and emtricitabine decreased the risk of rectal
transmission of simian immunodeficiency virus in macaques.68
Response to Public Comment
A draft version of this recommendation statement was posted for
public comment on theUSPSTFwebsite fromNovember 20, 2018,
to December 26, 2018. In response to public comment, the
USPSTF clarified language describing risk groups and high-risk ac-
tivities in the Clinical Considerations section. In the same section,
the USPSTF also added information about the high burden of HIV
in transgender women and the risk of HIV transmission in persons
living with HIV who have a suppressed viral load. The USPSTF also
addeddetails on the likelihood that specific activitieswill lead to the
transmissionofHIVandontheprevalenceofHIV indifferentgroups.
TheUSPSTFaddressedstigma,barriers toaccess to care, and racial/
ethnic disparities as obstacles to the use of PrEP by persons and
groups at high risk.
The USPSTF received comments requesting that it include a
meta-analysis69 examining the effects of PrEP on the risk of STIs in
the evidence reviewed for this recommendation. In response, the
USPSTF notes that it reviewed that particular meta-analysis; how-
ever, because of methodologic limitations of the studies included
in the meta-analysis, such as not adjusting for differential STI test-
ing ratesanduseof self-report todeterminebaselineSTI rates, itwas
not included in thebodyofevidenceconsidered for this recommen-
dation. Last, the USPSTF added the American College of Obstetri-
cians and Gynecologists committee opinion on the use of PrEP to
the Recommendations of Others section.
Recommendations of Others
The 2017 CDC guidelines recommend PrEP with tenofovir diso-
proxil fumarate/emtricitabine as anHIV prevention option formen
whohavesexwithmen,heterosexually activemenandwomen,and
persons who inject drugs who are at substantial risk of HIV infec-
tion, with tenofovir disoproxil fumarate monotherapy as an alter-
native for heterosexually activemen andwomen and personswho
inject drugs andwho are at substantial risk.3 The American College
of Obstetricians and Gynecologists suggests that, in combination
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with other proven HIV-prevention methods, PrEP may be a useful
tool for women at highest risk of HIV acquisition and that such
women should be considered candidates for PrEP.70 2016 World
Health Organization guidance recommends offering PrEP contain-
ing tenofovir disoproxil fumarateas anadditional preventionchoice
for persons at substantial risk of HIV infection (provisionally de-
finedasHIV incidencehigher than3cases/100person-years) aspart
of HIV prevention approaches.71
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